Premium
Cervical cancer chemoprevention, vaccines, and surrogate endpoint biomarkers
Author(s) -
Follen Michele,
Meyskens Frank L.,
Alvarez Ronald D.,
Walker Joan L.,
Bell Maria C.,
Adler Storthz Karen,
Sastry Jagannadha,
Roy Krishnendu,
RichardsKortum Rebecca,
Cornelison Terri L.
Publication year - 2003
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.11674
Subject(s) - medicine , surrogate endpoint , cervical cancer , clinical endpoint , clinical trial , cancer , hpv vaccines , randomized controlled trial , oncology , vaccine efficacy , disease , population , vaccine trial , intensive care medicine , hpv infection , immunology , vaccination , environmental health
At the Second International Conference on Cervical Cancer, held April 11–14, 2002, experts in cervical cancer prevention, detection, and treatment reviewed the need for more research in chemoprevention, including prophylactic and therapeutic vaccines, immunomodulators, peptides, and surrogate endpoint biomarkers. Investigators and clinicians noted the need for more rigorous Phase I randomized clinical trials, more attention to the risk factors that can affect study results in this patient population, and validation of optical technologies that will provide valuable quantitative information in real time regarding disease regression and progression. They discussed the role of the human papillomavirus (HPV) in cervical cancer development and the importance of developing strategies to suppress HPV persistence and progression. Results in Phase I randomized clinical trials have been disappointing because few have demonstrated statistically significant regression attributable to the agent tested. Researchers recommended using a transgenic mouse model to test and validate new compounds, initiating vaccine and immunomodulator trials, and developing immunologic surrogate endpoint biomarkers. Cancer 2003;98(9 Suppl):2044–2051. © 2003 American Cancer Society.